SI
EBS icon

Stirlingshire Investments’s Emergent Biosolutions EBS Stock Holding History

Stirlingshire Investments’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$160K Sell
19,285
-1,825
-9% -$18.9K 0.14% 194
2025
Q4 		$261K Buy
+21,110
New +$226K 0.23% 138

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Stirlingshire Investments's EBS Position: Q1 2026 in Review

Stirlingshire Investments reduced its Emergent Biosolutions (EBS) stake by 8.6% in Q1 2026, selling an estimated $18.9K and leaving 19,285 shares worth $160K. The position accounts for 0.14% of the portfolio, ranked #194.

Stirlingshire Investments first reported a position in EBS in Q4 2025 and has held it in 2 quarters since. The position peaked at $261K in Q4 2025. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • Stirlingshire Investments held 19,285 shares of Emergent Biosolutions worth $160K as of Q1 2026.
  • Stirlingshire Investments sold 1,825 Emergent Biosolutions shares in Q1 2026, an estimated $18.9K.
  • Emergent Biosolutions made up 0.14% of Stirlingshire Investments's portfolio in Q1 2026, its #194 holding.
  • Stirlingshire Investments first reported a position in Emergent Biosolutions in Q4 2025 and has held it in 2 quarters since.
  • Stirlingshire Investments's Emergent Biosolutions position peaked at $261K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Stirlingshire Investments's 13F filing for Q1 2026, filed 4 May 2026.